Islet Cell Tumors

Current Problems in Surgery

Volumn 43, Issue 10, 2006, Pages 685-765

  Mittendorf, Elizabeth A ^a   Inabnet, William B ^b   Libutti, Steven K ^c   McHenry, Christopher R ^d   Demeure, Michael J ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; ANTACID AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GASTRIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; LONG ACTING DRUG; OCTREOTIDE; OMEPRAZOLE; PACLITAXEL; PARATHYROID HORMONE RELATED PROTEIN; PENTETATE INDIUM IN 111; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNINDEXED DRUG;

ARTICLE; CANCER INCIDENCE; CARCINOID; CARDIOPULMONARY INSUFFICIENCY; CHEMOEMBOLIZATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; ENDOSCOPIC ECHOGRAPHY; ENUCLEATION; FISTULA; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL CARCINOMA; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PANCREAS SCINTISCANNING; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RADIOFREQUENCY ABLATION; SEPSIS; SOMATOSTATINOMA; STOMACH EMPTYING; SURGICAL TECHNIQUE; SURVIVAL RATE; SYMPTOM; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VIPOMA; VON HIPPEL LINDAU DISEASE; ZOLLINGER ELLISON SYNDROME;

ADRENOCORTICOTROPIC HORMONE; CARCINOID TUMOR; CARCINOMA, ISLET CELL; CUSHING SYNDROME; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PARATHYROID HORMONE-RELATED PROTEIN; POSTOPERATIVE CARE;

EID: 33749998650     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2006.07.003     Document Type: Article

References (306)

1. Buchanon K.D., Johnston C.F., O'Hare M.M.T., et al. Neuroendocrine tumours: a European view. Am J Med 81 (1986) 14-22
2. Solcia E., Capella C., and Klöppel G. Tumors of the Pancreas (1997), Armed Forces Institute of Pathology, Washington DC 3rd series
3. Heitz P.U., and Klöppel G. Pancreatic endocrine tumors. Path Res Pract 183 (1988) 155-168
4. Greider M.H., and Elliott D.W. Electron microscopy of human pancreatic tumors of islet cell origin. Am J Pathol 44 (1964) 663-678
5. Lloyd R.V., Mervak T., Schmidt K., Warner T.F.C.S., and Wilson B.S. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 8 (1984) 607-614
6. Tapia F.J., Barbosa A.J.A., Marangos P.J., Polak J.M., Bloom S.R., and Dermody C. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 2 (1981) 808-811
7. Capella C., Hietz P.U., Höfler H., Solcia E., and Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425 (1995) 547-560
8. Heymann M.F., Joubert M., Nemeth J., et al. Prognostic and immunohistochemical validation of the Capella classification of pancr4eatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology 36 (2000) 421-432
9. Klöppel G., Hietz P.U., Capella C., and Solcia E. Endocrine tumors of the pancreas. In: Solcia E., Klöppel G., and Sobin L.H. (Eds). in collaboration with 9 pathologists from 4 countries. Histological Typing of Endocrine Tumours. 2nd ed. (2000), Springer-Verlag, Heidelberg 56-60
10. Compton C.C. Diseases of the pancreas. In: Weidner N. (Ed). The difficult diagnosis in surgical pathology (1996), WB Saunders, Philadelphia 270-272
11. Solcia E., Capella C., Fiocca R., Cornaggis M., and Bosi F. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am 18 (1989) 671-693
12. Graeme-Cook F., Bell D.A., Flotte I.-J., et al. Aneuploidy in pancreatic insulinomasdoes not predict malignancy. Cancer 66 (1990) 2365-2368
13. Donow C., Baisch H., Heitz P.U., and Klöppel G. Nuclear DNA content in 27 pancreatic endocrine tumors: correlation with malignancy, survival and expression of glycoprotein hormone alpha chain. Virchows Arch 419 (1991) 463-468
14. Pelosi G., Zamboni G., Doglioni C., et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignant in endocrine tumors of the pancreas. Am J Surg Pathol 16 (1992) 1215-1225
15. Clarke M.R., Baker E.E., Weyant R.J., Hill L., and Carty S.E. Proliferative activity in pancreatic endocrine tumors: association with function, metastases and survival. Endocr Pathol 8 (1997) 181-187
16. Fisher W.E., and Brunicardia F.C. Zollinger-Ellison syndrome. In: Cameron J. (Ed). Current Surgical Therapy. 8th ed. (2004), Mosby, Philadelphia, PA 76-79
17. Roy P., Venzon D.J., Shojamanesh H., Abou-Saif A., Peghini P., Doppman J.L., et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 79 (2000) 379-411
18. Modlin I.M., Jaffe B.M., Sank A., and Albert D. The early diagnosis of gastrinoma. Ann Surg 196 (1982) 512-517
19. Townsend Jr. C.M., and Thompson J.C. Up-to-date treatment of patients with gastrinoma. Adv Surg 20 (1987) 155-181
20. Norton J.A., Fraker D.L., Alexander H.R., Venzon D.J., Doppman J.L., Serrano J., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
21. Ellison E.H., and Wilson S.D. The Zollinger-Ellison syndrome: reappraisal and evaluation of 260 registered cases. Ann Surg 160 (1964) 512-530
22. Norton J.A., Doppman J.L., Collen M.J., et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 204 (1986) 468-479
23. Soga J., and Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 5 (1998) 77-85
24. Cameron A.J., and Hoffman H.N. Zollinger-Ellison syndrome; clinical features and long-term follow-up. Mayo Clin Proc 49 (1974) 44-51
25. Christlieb A.R., and Schuster M.M. Zollinger-Ellison syndrome. Arch Intern Med 114 (1964) 381-388
26. Ellison E.H., and Wilson S.D. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 160 (1964) 512-530
27. Farley D.R., Van Heerden J.A., Grant C.S., Miller L.J., and Ilstrup D.M. The Zollinger-Ellison syndrome. A collective surgical experience. Ann Surg 215 (1992) 561-569
28. Kaplan E.L., Horvath K., Udekwu A., Straus F., Schark C., Ferguson D.J., and Skinner D.B. Gastrinomas: a 42-year experience. World J Surg 14 (1990) 365-375
29. Regan P.T., and Malagelada J.R. A reappraisal of clinical, roentgenographic, and endoscopic features of the Zollinger-Ellison syndrome. Mayo Clin Proc 53 (1978) 19-23
30. Stage J.G., and Stadil F. The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol 53 (1979) 79-91
31. Thompson J.C., Reeder D.D., Villar H.V., and Fender H.R. Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome. Surg Gynecol Obstet 140 (1975) 721-739
32. Way L., Goldman L., and Dunphy J.E. Zollinger-Ellison syndrome. An analysis of twenty-five cases. Am J Surg 116 (1968) 293-304
33. Lenert J.T., Bold R.J., Sussman J.J., and Tyler D.S. Pancreatic endocrine tumors and multiple endocrine neoplasia. In: Feig B., Berger D.H., and Fuhrman G.M. (Eds). The MD Anderson Surgical Oncology Handbook. 3rd ed. (2004), Lippincott Williams & Wilkins, Philadelphia 324-351
34. Ellison E.C., and Sparks J. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors?. Am J Surg 186 (2003) 245-248
35. Corleto V.D., Annibale B., Gibril F., Angeletti S., Serrano J., Venzon D.J., et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Aliment Pharmacol Ther 15 (2001) 1555-1561
36. Fishbeyn V.A., Norton J.A., Benya R.V., Pisegna J.R., Venzon D.J., Metz D.C., et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Int Med 119 (1993) 199-206
37. Wolfe M.M., and Jensen R.T. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 317 (1987) 1200-1209
38. McGuigan J.E., and Trudeau W.L. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 278 (1968) 1308-1318
39. Jensen R.T., Gardner J.D., and Raufman J.P. Zollinger-Ellison syndrome: NIH combined clinical staff conference. Ann Intern Med 98 (1983) 59-75
40. Meko J.B., and Norton J.A. Gastrinoma. In: Beger H.G., Warshaw A.L., Büchler M.W., Carr-Locke D.L., Neoptolemos J.P., Russell C., et al. (Eds). The Pancreas (1988), Blackwell Science, Oxford 1228-1253
41. Frucht H., Howard J.M., Slaff J.E., et al. Secretin and calcium provocative tests in patients with Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 111 (1989) 713-722
42. Deveney C.W., Deveney K.S., Jaffe B.M., et al. Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome). Ann Intern Med 87 (1977) 680-686
43. Jensen R.T. Zollinger-Ellison syndrome. In: Doherty G.M., and Skogscid B. (Eds). Surgical Endocrinology: Clinical Syndromes (2001), Lippincott Williams & Wilkins, Philadelphia 291-344
44. Alexander H.R., Fraker D.L., Norton J.A., Bartlett D.L., Tio L., Benjamin S.B., et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228 (1998) 228-238
45. Cadiot G., Lebtahi R., Sarda L., Bonnaud G., Marmuse J.P., Vissuzaine C., et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 111 (1996) 845-854
46. Frucht H., Norton J.A., London J.F., Vinayek R., Doppman J.L., Gardner J.D., et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology 99 (1990) 1622-1627
47. Howard T.J., Zinner M.J., Stabile B.E., and Passaro Jr. E. Gastrinoma excision for cure: a prospective analysis. Ann Surg 211 (1990) 9-14
48. Jordan Jr. P.H. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg 189 (1999) 470-482
49. Norton J.A., Doppman J.L., and Jensen R.T. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 215 (1992) 8-18
50. Sugg S.L., Norton J.A., Fraker D.L., Metz D.C., Pisegna J.R., Fishbeyn V., et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 218 (1993) 138-144
51. Weber H.C., Venzon D.J., Lin J.T., Fishburn V.A., Orbuch M., Strader D.B., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 (1995) 1637-1649
52. Zogakis T.G., Gibril F., Libutti S.K., Norton J.A., White D.E., Jensen R.T., et al. Management and outcome of patients with sporadic gastrinomas arising in the duodenum. Ann Surg 238 (2003) 42-48
53. Maton P.N., Mackem S.M., Norton J.A., Gardner J.D., O'Dorisio T.M., and Jensen R.T. Ovarian carcinoma as a cause of Zollinger-Ellison syndrome: natural history, secretory products, and response to provocative tests. Gastroenterology 97 (1989) 468-471
54. Wu P.C., Alexander H.R., Bartlett D.L., Doppman J.L., Fraker D.L., Norton J.A., et al. A prospective analysis of the frequency, location and curability of ectopic (nonpancreaticoduodenal nonnodal) gastrinoma. Surgery 122 (1997) 1176-1182
55. Yu F., Venzon D.J., Serrano J., Goebel S.U., Doppman J.L., Gibril F., et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 17 (1999) 615-630
56. Corleto V.D., Delle Fave G., and Jensen R.T. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis 34 (2002) 668-680
57. Serrano J., Goebel S.U., Peghni P.L., Lubensky I.A., Gibril F., and Jensen R.T. Alterations in the p16 INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85 (2000) 4146-4156
58. Goebel S.U., Heppner C., Burns A.L., Marx S.J., Spiegel A.M., Zhuang Z., et al. Genotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab 85 (2000) 116-123
59. Muscarella P., Melvin W.S., Fisher W.E., For J., Ellison E.C., Harman J.G., et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 58 (1998) 237-240
60. Goebel S.U., Iwamoto M., Raffeld M., Gibril F., Hou W., Serrano J., et al. Her2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62 (2002) 3702-3710
61. Peghini P.L., Iwamoto M., Raffeld M., Chen Y.J., Goebel S.U., Serrano J., et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8 (2002) 2273-2285
62. Sutliff V.E., Doppman J.L., Gibril F., Yu F., Serrano J., Venzon D.J., et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 15 (1997) 2420-2431
63. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy. Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1006;125:26-34.
64. de Kerviler E., Cadiot G., Lebtahi R., Faraggi M., Le Guludec D., and Mignon M. Somatostain receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med 21 (1994) 1191-1197
65. Norton J.A., and Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 (2004) 757-773
66. Dromain C., de Baere T., Lumbroso J., Caillet H., Laplanche A., Boige V., et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 (2005) 70-78
67. Foley W.D., Mallisee T.A., Hohenwalter M.D., Wilson C.R., Quiroz F.A., and Taylor A.J. Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol 175 (2000) 679-685
68. Paulson E.K., McDermott V.G., Keogan M.T., DeLong D.M., Frederick M.G., and Nelson R.C. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206 (1998) 143-150
69. Donow C., Pipeleers-Marichal M., Schroder S., Stamm B., Heitz P.U., and Kloppel G. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 68 (1991) 1329-1334
70. DeAngelis C., Carucci P., Repici A., and Rizzetto M. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound 10 (1999) 139-150
71. Proye C., Malvaux P., Pattou F., Filoche B., Godchaux J.M., Maunoury V., et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 124 (1998) 1134-1144
72. Ruszniewski P., Amouyal P., Amouyal G., Grange J.D., Mignon M., Bouche O., et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 117 (1995) 629-635
73. Zimmer T., Stolzel U., Bader M., Koppenhagen K., Hamm B., Buhr H., et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut 39 (1996) 562-568
74. Anderson M.A., Carpenter S., Thompson N.W., Nostrant T.T., Elta G.H., and Scheiman J.M. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95 (2000) 2271-2277
75. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.L., Gibril F., and Jensen R.T. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234 (2001) 495-506
76. Wamsteker E.J., Gauger P.G., Thompson N.W., and Scheiman J.M. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 58 (2003) 531-535
77. Gauger P.G., and Thompson N.W. Early surgical intervention and strategy in patients with multiple endocrine neoplasia type 1. Best Pract Res Clin Endocrinol Metab 15 (2001) 213-223
78. Thompson N.W. Multiple endocrine neoplasia type I: surgical therapy. Cancer Treat Res 89 (1997) 407-419
79. McHenry C.R. Pancreatic islet cell tumors. In: Baker R.J., and Fischer J.E. (Eds). Mastery of Surgery. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 552-559
80. Ellison E.C., Carey L.C., Sparks J., O'Dorisio T.M., Mekhjian H.S., Fromkes J.J., et al. Early surgical treatment of gastrinoma. Am J Med 82 (1987) 17-24
81. Ellison E.C. Forty year appraisal of gastrinoma: back to the future. Ann Surg 222 (1995) 511-524
82. Fraker D.L., and Jensen R.T. Pancreatic endocrine tumors. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles & Practice of Oncology (1997), Lippincott-Raven, Philadelphia 1678-1704
83. Brentjens R., and Saltz L. Islet cell tumors of the pancreas. The medical oncologist's perspective. Surg Clin North Am 81 (2001) 527-554
84. Norton J.A., Cromack D.T., Shawker T.H., Doppman J.L., Comi R., Gorden P., et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg 207 (1988) 160-168
85. Norton J.A., and Jensen R.T. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 12 (2003) 145-151
86. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., and Jensen R.T. Does the routine use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg 239 (2004) 617-625
87. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., and Jensen R.T. Does the routine use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg 239 (2004) 617-625
88. Jensen R.T., and Fraker D.L. Zollinger-Ellison syndrome: advances in treatment of the gastric hypersecretion and the gastrinoma. JAMA 271 (1994) 1-7
89. Berends F.J., Cuesta M.A., Kazemier G., van Eijck C.H., de Herder W.W., Bruining H.A., et al. Laparoscopic detection and resection of insulinomas. Surgery 128 (2000) 386-391
90. Fernandez-Cruz L., Saenz A., Astudillo E., Martinez I., Hoyos S., Pantoja J.P., et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 26 (2002) 1057-1065
91. Furihata M., Tagaya N., and Kubota K. Laparoscopic enucleation of insulinoma in the pancreas: case report and review of the literature. Surg Laparosc Endosc Percutan Tech 11 (2001) 279-283
92. Iihara M., Kanbe M., Okamoto T., Ito Y., and Obara T. Laparoscopic ultrasonography for resection of insulinomas. Surgery 130 (2001) 1086-1091
93. Spitz J.D., Lilly M.C., Tetik C., and Arregui M.E. Ultrasound-guided laparoscopic resection of pancreatic islet cell tumors. Surg Laparosc Endosc Percutan Tech 10 (2000) 168-173
94. Underwood R.A., and Soper N.J. Current status of laparoscopic surgery of the pancreas. J Hepatobil Pancreat Surg 6 (1999) 154-164
95. Iihara M., Kanbe M., Okamoto T., Ito Y., and Obara T. Laparoscopic ultrasonography for resection of insulinomas. Surgery 130 (2001) 1086-1091
96. Norton J.A., and Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 (2004) 757-773
97. Alexander H.R., Bartlett D.L., Venzon D.J., Libutti S.K., Doppman J.L., Fraker D.L., et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 124 (1998) 1153-1159
98. Fishbeyn V.A., Norton J.A., Benya R.V., Pisegna J.R., Venzon D.J., Metz D.C., et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med 119 (1993) 199-206
99. Pisegna J.R., Norton J.A., Slimak G.G., Metz D.C., Maton P.N., and Jensen R.T. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 102 (1992) 767-778
100. Metz D.C., Benya R.V., Fishbeyn V.A., Pisegna J.R., Obruch M., Strader D.B., et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther 7 (1993) 247-257
101. Perry R.R., and Vinik A.I. Endocrine tumors of the gastrointestinal tract. Annu Rev Med 47 (1996) 57-68
102. Azimuddin K., and Chamberlain R.S. The surgical management of pancreatic neuroendocrine tumors. Surg Clin of North Am 81 (2001) 511-525
103. Alexander H.R., and Jensen R.T. Pancreatic endocrine tumors. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles & Practice of Oncology (1997), Lippincott-Raven, Philadelphia 1788-1813
104. Madeira I., Terris B., Voss M., Denys A., Sauvanet A., Flejou J.F., et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 (1998) 422-427
105. Eriksson B., Skogseid B., Lundqvist G., Wide L., Wilander E., and Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 (1990) 1883-1890
106. Carty S.E., Jensen R.T., and Norton J.A. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112 (1992) 1024-1031
107. McEntee G.P., Nagorney D.M., Kvols L.K., Moertel C.G., and Grant C.S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
108. Nagorney D.M., and Que F.G. Cytoreductive hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. In: Mignon M., and Jensen R.T. (Eds). Endocrine Tumors of the Pancreas: Recent Advances in Research and Management: Series: Frontiers of Gastrointestinal Research (1995), Karger, Basel, Switzerland 416-430
109. Norton J.A., Sugarbaker P.H., Doppman J.L., Wesley R.A., Maton P.N., Gardner J.D., et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 203 (1986) 352-359
110. Elias D., Lasser P., Ducreux M., Duvillard P., Ouellet J.F., Dromain C., et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133 (2003) 375-382
111. Norton J.A., Warren R.S., Kelly M.G., Zuraek M.B., and Jensen R.T. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134 (2003) 1057-1065
112. Que F.G., Nagorney D.M., Batts K.P., Linz L.J., and Kvols L.K. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 (1995) 36-43
113. Thom AK, Norton JA, Doppman JL, Miller DL, Chang R, Jensen RT. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1002;112:1002-8.
114. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastasis: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
115. McEnter G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
116. Metz D.C., Strader D.B., Orbuch M., Koviack P.D., Feigenbaum K.M., and Jensen R.T. Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 7 (1993) 597-610
117. Metz D.C., Pisegna J.R., Fishbeyn V.A., Benya R.V., Feigenbaum K.M., Koviack P.D., et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 103 (1992) 1498-1508
118. Service F.J., McMahon M.M., O'Brien P.C., et al. Functioning insulinoma-incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc 66 (1991) 711-719
119. Whipple A.O., and Franz V.K. Adenoma of islet cells with hyperinsulinism. Am Surg 101 (1935) 1299-1355
120. Grant C.S. Insulinoma. Surg Oncol Clin North Am 7 (1998) 819-844
121. Service F.J., Dale A.J.D., Elveback I.R., et al. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 51 (1976) 417-429
122. Arnold R., Frank M., and Bülchman G. Insulinoma and persistent neonatal hyperinsulinemic hypoglycemia (nesidioblastosis). In: Beger H.G., Warshaw A.L., Bücher M.W., Carr-Locke D.L., Neoptolemos J.P., Russel C., et al. (Eds). The Pancreas (1998), Blackwell Science, Oxford 1187-1202
123. Turner R.C., and Keding I. Plasma proinsulin, C-peptide and insulin in diagnostic suppression test for insulinomas. Diabetologia 13 (1977) 571-577
124. Boukhman M.P., Karam J.M., Shaver J., Siperstein A.E., DeLorimier A.A., and Clark O.H. Localization of insulinomas. Arch Surg 134 (1999) 818-823
125. Gianello P., Gigot J.F., Berthet F., et al. Pre- and intraoperative localization of insulinomas: report of twenty-two observations. World J Surg 12 (1988) 389-397
126. Doherty G.M., Doppman J.L., Shawker T.H., et al. Results of a prospective strategy to diagnose, localize and resect insulinomas. Surgery 110 (1991) 989-997
127. Bottger T.C., Weber W., Beyer J., and Junginger T. Value of tumor localization in patients with insulinoma. World J Surg 14 (1990) 107-114
128. Felder J.L., Fletcher J.G., Reading C.C., et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 181 (2003) 775-780
129. Theoni R.F., Mueller-Lisse U.G., Chan R., Do N.K., and Shyn P.B. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214 (2000) 483-490
130. Catalano C., Pavone P., Laghi A., et al. Localization of pancreatic insulinomas with MR imaging at 0.5 T. Acta Radiol 40 (1999) 644-648
131. Grant C.S. Surgical aspects of hyperinsulinemic hypoglycemia. Endocrinol Clin North Am 28 (1999) 533-554
132. Bansal R., Tierney W., Carpenter S., Thompson N., and Scheiman J.M. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 49 (1999) 19-25
133. Gouya H., Vignaux O., and Augui J. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181 (2003) 987-992
134. Bertherat F., Tenenbaum K., Perlemoine C., et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88 (2003) 5353-5360
135. Lamberts S.W., Kenning E.P., and Reubi J.C. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocr Rev 12 (1991) 450-482
136. Perry RR, Vinik AI: Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1195;80:2273-78.
137. Schillaci O., Massa R., and Scopinaro F. 111In-pentecreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 41 (2000) 459-462
138. Won J.G.S., Tseng H.-S., Yan A.-H., et al. Intra-arterial calcium stimulation test for detection of insulinomas: Detection rate, responses to pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism 52 (2003) 1320-1329
139. Hiramoto J.S., Feldstein V.A., LaBerge J.M., and Norton J.A. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 136 (2001) 1020-1025
140. Imamura M., Takahashi K., Adashi H., et al. Usefulness of selective arterial secretin injection test for localization of gastrinomas in the Zollinger-Ellison syndrome. Ann Surg 205 (1987) 230-239
141. Doppman J.L., Miller J.L., Chang R., et al. Insulinoma: Localization with selective intraarterial injection of calcium. Radiology 178 (1991) 237-241 1991
142. Prentki M., and Matschinsky F.M. Ca2+, cAMP, and phospholipids-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 67 (1987) 1185-1248
143. Brown C.K., Bartlett D.L., Doppman J.L., et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 122 (1997) 1189-1194
144. Rothmund M., Angelini L., Brunt M., et al. Surgery for benign insulinoma: an international review. World J Surg 14 (1990) 393-399
145. Grant C.S., vanHeerden J.A., Charboneau J.W., et al. Insulinoma: the value of intraoperative ultrasonography. Arch Surg 123 (1988) 843-847
146. Carniero D.M., Levi J.U., and Irvin III G.L. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery 132 (2002) 937-943
147. Fajans S.S., and Vinik A.I. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 18 (1989) 45-74
148. Stefanini P., Carboni M., Patrassi N., and Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1067 cases. Surgery 75 (1974) 597-609
149. Sarr M.G., and Pancreatic Surgery Group. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. JACS 196 (2003) 556-565
150. Gagner M., Pomp A., and Herrera M.F. Early experience with laparoscopic resections of islet cell tumors. Surgery 120 (1996) 1051-1054
151. Fernandez-Cruz L., Sáenz A., Astudillo E., et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 26 (2002) 1057-1065
152. Berends F.J., Cuesta M.A., Kazemier G., et al. Laparoscopic detection and resection of insulinomas. Surgery 128 (2000) 386-391
153. Park A.E., and Heniford B.T. Therapeutic laparoscopy of the pancreas. Ann Surg 236 (2002) 149-158
154. Kaplan E.L., and Lee C.-H. Recent advances in the diagnosis and treatment of insulinomas. Surg Clin North Am 59 (1979) 119-129
155. Thompson G.B. Insulinoma. In: Prinz R.A., and Staren E.D. (Eds). Endocrine Surgery. Endocrine Surgery (2000), Landes Bioscience, Georgetown TX 222-228
156. Harrison T.S., Child III C.G., Fry W.J., et al. Current surgical management of functioning islet-cell tumors of the pancreas. Ann Surg 178 (1973) 485-495
157. Kaplan E.L., and Lee C.-H. Recent advancements in the diagnosis and treatment of insulinomas. Surg Clin North Am 59 (1979) 119-129
158. Proye C.A., Pattou F., Carnaille B., Lefebvre J., Decoulx M., and d'Herbomez M. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg 22 (1998) 1218-1224
159. Stefanini P., Carboni M., Patrassi N., and Basoli A. Hypoglycemia and insular hyperplasia. Ann Surg 180 (1974) 130-135
160. Harrison T.S., Fajans S.S., Floyd Jr. J.C., et al. Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism: problems in recognition and management. World J Surg 8 (1984) 583-589
161. Thompson G.B., Service F.J., Andrews J.C., et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 128 (2000) 937-945
162. Service F.J., McMahon M.M., O'Brien P.C., et al. Functioning insulinoma-incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc 66 (1991) 711-719
163. McEntee G.P., Nagorney D.M., Kvols L.K., Moertel C.G., and Grant C.S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
164. Soga J. The Niigata registry for gut-pancreatic endocrinomas: maintenance, analysis and supply with Windows version. Bull Niigata Seiryo Univ 4 (2004) 39-55
165. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
166. Pataky Z., Nagy L., and Popik E. Uber einen vomPankreaskopf hervorgehenden primarin Argentaffintumorbefall. Zentralbl Allg Pathol 99 (1959) 442-444
167. Soga J. Carcinoids of the pancreas: an analysis of 156 cases. Cancer 104 (2005) 1180-1187
168. Verner J.V., and Morrison A.B. Non-beta islet cell tumors and the syndrome of watery diarrhea, hypokalemia, and hypochlorhydria. Clin Gastroenterol 3 (1974) 595-608
169. Murray J.S., Paton R.R., and Pope II C.E. Pancreatic tumor associated with flushing and diarrhea. N Engl J Med 264 (1961) 436-439
170. Verner J.V., and Morrison A.B. Endocrine pancreatic islet cell disease with diarrhea: report of a case due to diffuse hyperplasia of non-beta islet tissue with a review of 54 additional cases. Arch Intern Med 133 (1974) 492-500
171. Capella C., Polak J.M., Buffa R., et al. Morphological patterns and diagnostic criteria of VIP producing endocrine tumors: a histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 52 (1983) 1860-1874
172. O'Dorisio T.M., and Mekjian H.S. VIPoma syndrome. In: Cohen S., and Soloway R.D. (Eds). Contemporary Issues in Gastroenterology (1984), Churchill Livingstone, New York 101-116
173. Fausa O., Fretheim B., Elgjo K., et al. Intractable watery diarrhea, hypokalemia, and achlorhydria associated with non-pancreatic retroperitoneal neurogenous tumour containing vasoactive intestinal peptide. Scand J Gastroenterol 8 (1973) 713-717
174. Said S.I., and Faloona G.R. Elevated plasma and tissue levels of vasoactive intestinal peptide in watery diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med 293 (1975) 155-160
175. Watson K.J.R., Shulkes A., Smallwood R.A., et al. Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. Gastroenterology 88 (1985) 798-803
176. Wynick D., Williams S.J., and Bloom S.R. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319 (1988) 605-607
177. Edney J.A., Hofmann S., Thompson J.S., and Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg 160 (1990) 625-629
178. Prinz R.A., Sagimoto J., Lorincz A., et al. Glucagonoma. In: Howard J.M., Jordan Jr. G.L., and Reber H.A. (Eds). Surgical Diseases of the Pancreas (1987), Lea & Febiger, Philadelphia 848-857
179. Prinz R.A., Dorsch T.R., Lawrence A.M., et al. Clinical aspects of glucagon producing islet cell tumors. Am J Gastroenterol 76 (1981) 125-131
180. Bordi C., Yu J.Y., Girolami A., et al. Immunohistochemical localization of factor X-like antigen in pancreatic islets and their tumours. Virchows Arch A 416 (1990) 397-402
181. Altimari A.F., Bhoopalam N., O'Dorisio T., Lange C.L., Sandberg L., and Prinz R.A. Use of somatostatin analogue (SMS 201-995) in the glucagonoma syndrome. Surgery 100 (1986) 989-996
182. Krejs G.S., Orchi L., Conlon J.M., et al. Somatostatinoma syndrome: biochemical, morphologic and clinical features. N Engl J Med 301 (1979) 285
183. Vinik A.L., Strodel W.E., Eckhauser F.E., et al. Somatostatinomas, VIPomas and neurotensinomas. Semin Oncol 14 (1987) 263-281
184. Konomi K., Chijiwa K., Katsuta T., et al. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol 43 (1990) 259
185. Larsson L.I., Holst J.J., Kuhl C., et al. Pancreatic somatostatinoma: clinical features and physiological implications. Lancet 1 (1977) 666-669
186. Eckhause F.E., and Colletti L.M. Somatostatinoma. In: Beger H.G., Warshaw A.L., Büchler M.W., Carr-Locke D.L., Neoptolemos J.P., Russell C., et al. (Eds). The Pancreas (1998), Blackwell Science, London 1270-1274
187. Orth D.N. Cushing's syndrome. N Engl J Med 332 (1995) 791-803
188. Amikura K., Alexander H.R., Norton J.A., et al. Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Surgery 118 (1995) 1125-1130
189. Clark E.S., and Carney J.A. Pancreatic islet cell tumor associated with Cushing's syndrome. Am J Surg Pathol 8 (1984) 917-924
190. Graham B.S., and Tucker Jr. W.S. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 101 (1984) 334-338
191. Law D.H., Liddle G.W., Scott Jr. W., and Tauber S.D. Ectopic production of multiple hormones (ACTH, MSH and gastrin) by a single malignant tumor. N Engl J Med 273 (1965) 292-296
192. Mao C., Carter P., Schaefer P., et al. Malignant islet cell tumor associated with hypercalcemia. Surgery 117 (1995) 37-40
193. Miraliakbari B.A., Asa S.L., and Boudreau S.F. Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol 23 (1992) 884-887
194. Kao P.C., Klee G.G., Taylor R.L., and Heath III H. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clin Proc 65 (1990) 1399-1407
195. Wynick D., Ratcliffe W.A., Heath D.A., et al. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related peptide. BMJ 300 (1990) 1314-1315
196. Evans D.B., Skibber J.M., Lee J.F., et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114 (1993) 1175-1181
197. Solorzano C.C., Lee J.F., Pister P.W.T., et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 (2000) 1078-1085
198. Merrell R.C., and Evans D.B. Pancreatic Polypeptide-Producing and Nonfunctioning Islet Cell Tumors of the Pancreas. The Pancreas. 1st ed. Vol. 2 (1998), Oxford, Blackwell Science Ltd 1275-1283
199. Bartsch D.K., Schilling T., Ramaswamy A., et al. Management of nonfunctioning islet cell carcinomas. World J Surg 24 (2000) 1418-1424
200. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 (1997) 404-407
201. Skogseid B., Rastad J., and Akerstrom G. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1. In: Doherty G., and Skogseid B. (Eds). Surgical Endocrinology. 1st ed. (2001), Lippincott Williams & Wilkins, New York 511-524
202. Agarwal S.K., Kennedy P.A., Scacheri P.C., Novotny E.A., Hickman A.B., Cerrato A., et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37 (2005) 369-374
203. Alexakis N., Connor S., Ghaneh P., Lombard M., Smart H.L., Evans J., et al. Hereditary pancreatic endocrine tumours. Pancreatology 4 (2004) 417-433 discussion 434-5
204. Marx S., Spiegel A.M., Skarulis M.C., Doppman J.L., Collins F.S., and Liotta L.A. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern 129 (1998) 484-494
205. Marx S.J., Agarwal S.K., Kester M.B., Heppner C., Kim Y.S., Emmert-Buck M.R., et al. Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). J Intern Med 243 (1998) 447-453
206. Marx S.J., Agarwal S.K., Kester M.B., Heppner C., Kim Y.S., Skarulis M.C., et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 54 (1999) 397-438 discussion 438-399
207. MacFarlane M.P., Fraker D.L., Alexander H.R., Norton J.A., Lubensky I., and Jensen R.T. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 118 (1995) 973-979 discussion 979-80
208. Norton J.A., Fraker D.L., Alexander H.R., Venzon D.J., Doppman J.L., Serrano J., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
209. Alexander H.R., Bartlett D.L., Venzon D.J., Libutti S.K., Doppman J.L., Fraker D.L., et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 124 (1998) 1160-1166
210. Hirshberg B., Livi A., Bartlett D.L., Libutti S.K., Alexander H.R., Doppman J.L., et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 85 (2000) 3222-3226
211. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243 (1998) 495-500
212. Doherty G., and Jensen R.T. Multiple endocrine neoplasias. In: Devita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles & Practice of Oncology. 7th ed. (2005), Lippincott Williams & Wilkins, New York 1575-1580
213. Doppman J.L., Chang R., Fraker D.L., Norton J.A., Alexander H.R., Miller D.L., et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 123 (1995) 269-273
214. Doppman J.L., Miller D.L., Chang R., Gorden P., Eastman R.C., and Norton J.A. Intraarterial calcium stimulation test for detection of insulinomas. World J Surg 17 (1993) 439-443
215. Schussheim D.H., Skarulis M.C., Agarwal S.K., Simonds W.F., Burns A.L., Spiegel A.M., et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12 (2001) 173-178
216. Libutti S.K., Choyke P.L., Bartlett D.L., Vargas H., Walther M., Lubensky I., et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 124 (1998) 1153-1159
217. Libutti S.K., Choyke P.L., Alexander H.R., Glenn G., Bartlett D.L., Zbar B., et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 128 (2000) 1022-1027 discussion 1027-8
218. Lubensky I.A., Pack S., Ault D., Vortmeyer A.O., Libutti S.K., Choyke P.L., et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153 (1998) 223-231
219. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., et al. von Hippel-Lindau disease. Lancet 361 (2003) 2059-2067
220. Walther M., Linehan W.M., and Libutti S.K. von Hippel-Lindau disease and von Recklinghausen's cisease. In: Doherty G., and Skogseid B. (Eds). Surgical Endocrinology. 1st ed. (2001), Lippincott Williams & Wilkins, New York 581-591
221. Na X., Wu G., Ryan C.K., Schoen S.R., di'Santagnese P.A., and Messing E.M. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170 (2003) 588-592
222. Wang Y.Q., Luk J.M., Ikeda K., Man K., Chu A.C., Kaneda K., et al. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 317 (2004) 358-362
223. Wheeler M.H., Curley I.R., and Williams E.D. The association of neurofibromatosis, pheochromocytoma, and somatostatin-rich duodenal carcinoid tumor. Surgery 100 (1986) 1163-1169
224. Mao C., Shah A., Hanson D.J., and Howard J.M. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59 (1995) 67-73
225. Sood G.K., Chaudhry A., Malhotra V., and Broor S.L. Pancreatic cystadenoma associated with von Recklinghausen's disease. Indian J Gastroenterol 10 (1991) 148-149
226. Lukash W.M., Morgan R.I., Sennett C.O., and Nielson O.F. Gastrointestinal neoplasms in von Recklinghausen's disease. Arch Surg 92 (1966) 905-908
227. Keller R.T., and Logan Jr. G.M. Adenocarcinoma of the pancreas associated with neurofibromatosis. Cancer 39 (1977) 1264-1266
228. Mak B.C., Takemaru K., Kenerson H.L., Moon R.T., and Yeung R.S. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 278 (2003) 5947-5951
229. Verhoef S., van Diemen-Steenvoorde R., Akkersdijk W.L., Bax N.M., Ariyurek Y., Hermans C.J., et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 158 (1999) 284-287
230. Knaebel H.P., Diener M.K., Wente M.N., Buchler M.W., and Seiler C.M. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 92 (2005) 539-546
231. Mabrut J.Y., Fernandez-Cruz L., Azagra J.S., Bassi C., Delvaux G., Weerts J., et al., Hepatobiliary and Pancreatic Section (HBPS) of the Royal Belgian Society of Surgery, Belgian Group for Endoscopic Surgery (BGES), Club Coelio. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 137 (2005) 597-605
232. Patterson E.J., Gagner M., Salky B., Inabnet W.B., Brower S., Edye M., et al. Laparoscopic pancreatic resection: single-institution experience of 19 patients. J Am Coll Surg 193 (2001) 281-287
233. Fernandez-Cruz L., Martinez I., Gilabert R., Cesar-Borges G., Astudillo E., and Navarro S. Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg 8 (2004) 493-501
234. Dulucq J.L., Wintringer P., Stabilini C., Feryn T., Perissat J., and Mahajna A. Are major laparoscopic pancreatic resections worthwhile?. A prospective study of 32 patients in a single institution. Surg Endosc 19 (2005) 1028-1034
235. Gagner M., and Pomp A. Laparoscopic pancreatic resection: is it worthwhile?. J Gastrointest Surg 1 (1997) 20-26
236. Kuroki T., Tajima Y., and Kanematsu T. Surgical management for the prevention of pancreatic fistula following distal pancreatectomy. J Hepatobiliary Pancreat Surg 12 (2005) 283-285
237. Lin J.W., Cameron J.L., Yeo C.J., et al. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg 8 (2004) 951-959
238. Efron D.T., Lillemoe K.D., Cameron J.L., and Yeo C.J. Central pancreatectomy with pancreaticogastrostomy for benign pancreatic pathology. J Gastrointest Surg 8 (2004) 532-538
239. Schmidt C.M., Powell E.S., Yiannoutsos C.T., et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 139 (2004) 718-725
240. de Castro S.M., Kuhlmann K.F., Busch O.R., et al. Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery?. Ann Surg 241 (2005) 85-91
241. Choi S.H., Moon H.J., Heo J.S., et al. Delayed hemorrhage after pancreaticoduodenectomy. J Am Coll Surg 199 (2004) 186-191
242. Horstmann O., Markus P.M., Ghadimi M.B., and Becker H. Pylorus preservation has no impact on delayed gastric emptying after pancreatic head resection. Pancreas 28 (2004) 69-74
243. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
244. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 (1995) 36-42
245. Choti M.A., Bowman H.M., Pitt H.A., et al. Should hepatic resections be performed at high-volume referral centers?. J Gastrointest Surg 2 (1998) 11-20
246. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
247. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes. J Am Coll Surg 190 (2000) 432-445
248. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 (2001) 677-685
249. Solorzano C.C., Lee J.E., Pisters P.W.T., et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 (2001) 1078-1085
250. Touzios J.G., Kiely J.M., Pitt S.C., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival. Ann Surg 241 (2005) 776-785
251. Abdalla E.K., Vauthey J.N., Ellis L.M., Ellis V., Pollock R., Broglio K.E., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004) 818-825
252. Curley S.A., Izzo F., Ellis L.M., Vauthey J.N., and Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhoses. Ann Surg 3 (2000) 381-391
253. Curley S.A., Izzo F., Abdalla E., and Vauthey J.N. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 23 (2004) 165-182
254. Siperstein A., Garland A., Engle K., Rogers S., Berber E., Foroutani A., et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 7 (2000) 106-113
255. Siperstein A., Garland A., Engle K., Rogers S., Berber E., String A., et al. Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Technical considerations. Surg Endosc 14 (2000) 400-405
256. Berber E., Flesher N., and Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26 (2002) 985-990
257. Hellman P., Ladjevardi S., Skogseid B., Akerstrom G., and Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26 (2002) 1052-1056
258. Siperstein A.E., Rogers S.J., Hansen P.D., and Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 122 (1997) 1147-1154
259. Seifert J.K., Cozzi P.J., and Morris D.L. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14 (1998) 175-183
260. Siperstein A.E., and Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (2001) 693-696
261. Le Truet Y.P., Delpero J.R., Dousset B., et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 225 (1997) 355-364
262. Marlink R.G., Lokich J.J., Robins J.R., and Clouse M.E. Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 15 (1990) 2227-2232
263. Clouse M.E., Perry L., Stuart K., and Stokes K.R. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 (1994) 92-97
264. Perry L.J., Stuart K., Stokes K.R., and Clouse M.E. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116 (1994) 1111-1116
265. Stokes K.R., Stuart K., and Clouse M.E. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 4 (1993) 341-345
266. Diamandidou E., Ajani J.A., Yang D.J., Chuang V.P., Brown C.A., Carrasco H.C., et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 170 (1998) 339-344
267. Ruszniewski P., Rougier P., Roche A., Legmann P., Sibert A., et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71 (1993) 2624-2630
268. Buscail L., Esteve J.P., Saint-Laurent N., et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92 (1995) 1580-1584
269. Lamberts S.W.J., Koper J.W., and Reubi J.C. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 17 (1987) 281-287
270. Delaunoit T., Rubin J., Neczyporenko F., Erlichman C., and Hobday T.J. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 80 (2005) 502-506
271. Kvols L.K., Reubi J.C., Horisberger U., Moertel C.G., Rubin J., and Charboneau J.W. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 65 (1992) 505-518
272. Schally A.V. Oncologic applications of somatostatin analogues. Cancer Res 48 (1985) 6977-6985
273. Wynick D., and Bloom S.R. The use of the long-acting somatostatin analogue octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 73 (1991) 1-3
274. Kvols L.K., Reubi J.C., Horisberger U., Moertel C.G., Rubin J., and Charboneau J.W. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 65 (1992) 505-518
275. Lamberts S.W., van der Lely A.J., de Herder W.W., and Hoflan L.J. Octreotide. N Engl J Med 334 (1996) 246-254
276. Wynick D., Anderson J.V., Williams S.J., and Bloom S.R. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf) 30 (1989) 385-388
277. Arnold R., Benning R., Neuhaus C., Rolwage M., and Trautman M.E. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth-the German Sandostatin Study Group. Digestion 54 (1992) 72-75
278. Ducreux M., Ruszniewski P., Chayvialle J.A., Blumberg J., Cloarec D., Michel H., et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95 (2000) 3276-3281
279. Shojamanesh H., Gibril F., Louie A., Ojeaburu J.V., Bashir S., Abou-Saif A., et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94 (2002) 31-343
280. Rubin J., Ajani J., Schirmer W., Venook A.P., Bukowski R., Pommier R., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 (1999) 600-606
281. Bajetta E., Zilembo N., Di Bartolomeo M., et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. Cancer 72 (1993) 3099-3105
282. Schöber C., Schmoll E., Schmoll H.-J., et al. Antitumour effect and symptomatic control with interferon α2b in patients with endocrine active tumours. Eur J Cancer 28A (1992) 1664-1666
283. Biesma B., Willemse P.H.B., Mulder N.H., et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumors and tumor markers. Br J Cancer 66 (1992) 850-855
284. Faiss S., Pape U.F., Böhmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanretotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 (2003) 2689-2696
285. Anthony L.B., Woltering E.A., Espanan G.D., Cronin M.D., Maloney T.J., and McCarthy K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
286. 111In-DTPA0]octreotide: the Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
287. Reubi C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
288. 111In-DTPA0]octreotide in patients. Eur J Nucl Med 28 (2001) 1319-1325
289. 177Lu-DOTA0Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
290. Moertel C., Myrto L., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
291. Gonzales M.A., Biswas S., and Corrie P.G. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89 (2003) 455-456
292. Fenteany G., and Schreiber S.L. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem Biol 3 (1996) 905-912
293. Shah M.H., Young D., Kindler H.L., et al. Phase II study of the proteosome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 (2004) 6111-6118
294. Kegel T, Grothe W, Jordan K Graubner M, Arnold D, Schmoll J. Paclitaxel, carboplatin, and etoposide (TCE) in the treatment of advanced neuroendocrine tumours. Presented as an abstract at the 2005 meeting of the American Society of Clinical Oncology. Orlando, FL, May 13-17, 2005.
295. Hainsworth J.D., Erland J.B., Kalman L.A., Schreeder M.T., and Greco F.A. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15 (1997) 2385-2393
296. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. Presented as an abstract at the 2005 meeting of the American Society of Clinical Oncology. Orlando, FL, May 13-17, 2005.
297. Broder L.E., and Carter S.K. Pancreatic islet cell carcinoma II. Results of therapy with streptozocin in 52 patients. Ann Intern Med 79 (1973) 108-118
298. Moertel C.G., Lavin P.T., and Hahn R.G. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 66 (1982) 1567-1569
299. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303 (1980) 1189-1194
300. Hoth D., Wooley B., Green D., Macdonald J., and Schein P. Phase I studies on chlorozotocin. Clin Pharmacol Ther 23 (1978) 712-722
301. Eriksson B., Oberg K., Alm G., Karlson A., Lundqvist G., Anderson T., et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 2 (1986) 1307-1309
302. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (1992) 519-523
303. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 (1999) 944-948
304. Rivera E., and Ajani J.A. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21 (1998) 36-38
305. Kouvaraki M.A., Ajani J.A., Hoff P., Wolff R., Evans D.B., Lozano R., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
306. von Schrenck T., Howard J.M., Doppman J.L., et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 94 (1988) 1326-1334